Previous 10 | Next 10 |
2023-05-12 18:39:02 ET Addex Therapeutics Ltd. (ADXN) Q1 2023 Earnings Conference Call May 11, 2023 10:00 AM ET Company Participants Timothy Dyer – Chief Executive Officer Robert Lütjens – Head of Discovery-Biology Conference Call Participant...
2023-05-11 05:57:49 ET Addex Therapeutics press release ( NASDAQ: ADXN ): Q1 GAAP EPS of -CHF0.04. Income increased by CHF 0.3 million to CHF 0.5 million in the first quarter 2023 compared to CHF 0.2 million in the first quarter 2022, primarily driven by amounts received u...
ADX71149 Phase 2 e pilepsy c linical s tudy’s i ndependent i nterim r eview c ommittee (“IRC”) r ecommends c ontinuing s tudy CHF 5.6M ($ 6.1 M) of cash and cash eq...
Cohort 1 progressing through P art 2 Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneer...
Geneva, Switzerland, May 4 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2023 financial results on Thursday, May ...
Proceeds to advance allosteric modulator therapeutic pipeline Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 5 , 202 3 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering alloster...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 4 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 3, 2023 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into ...
2023-03-31 17:55:23 ET Addex Therapeutics Ltd. (ADXN) Q4 2022 Results Conference Call March 30, 2023 10:00 AM ET Company Participants Timothy Dyer - CEO Robert Lutjens - Head, Discovery Biology Conference Call Participants Raghuram Selvaraju - H.C. Wainwr...
2023-03-30 01:38:53 ET Addex Therapeutics press release ( NASDAQ: ADXN ): FY GAAP EPS of -CHF 0.46. Income is primarily from our funded research collaboration with Indivior. Income decreased by CHF 1.7 million to CHF 1.4 million in 2022 compared to CHF 3.2 million in ...
News, Short Squeeze, Breakout and More Instantly...
Addex Therapeutics Ltd Company Name:
ADXN Stock Symbol:
NASDAQ Market:
Addex Therapeutics Ltd Website:
2024-07-19 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...